Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, New York, USA
Department of Epidemiology, Mailman School of Public Health, Columbia University Medical Center, New York, New York, USA.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01834-18. Print 2019 Apr.
A critical gap in tuberculosis (TB) treatment is detection of emergent drug resistance. We hypothesized that advanced phenotyping with whole-genome sequencing (WGS) will detect low-frequency drug resistance. We assessed a reporter mycobacteriophage (ΦGFP10) to detect drug-resistant subpopulations and predict bactericidal activity in this pilot study. Subsequently, we prospectively studied 20 TB patients with serial ΦGFP10, Xpert MTB/RIF, and culture through end of treatment. WGS was performed, and single nucleotide polymorphisms (SNPs) were examined to detect mixed infection in selected isolates. Resistant isolates were detected at 1:100,000, and changes in cytometry-gated events were predictive of bactericidal activity using the ΦGFP10 assay. Emergent drug resistance was detected in one patient by ΦGFP10 at 3 weeks but not by conventional testing ( culture and GeneXpert). WGS revealed a phylogeographically distinct extensively drug-resistant tuberculosis (XDR-TB) genome, identical to an XDR-TB isolate from the patient's spouse. Variant lineage-specific SNPs were present early, suggesting mixed infection as the etiology of emergent resistance with temporal trends providing evidence for selection during treatment. ΦGFP10 can detect low-frequency drug-resistant and with WGS characterize emergent resistance. In areas of high TB transmission and drug resistance, rapid screening for heteroresistance should be considered.
在结核病(TB)治疗中存在一个关键的缺口,那就是对新出现的耐药性的检测。我们假设,利用全基因组测序(WGS)进行高级表型分析将能够检测到低频耐药性。我们评估了一种报告型分枝杆菌噬菌体(ΦGFP10),以检测耐药亚群并预测该噬菌体在本试验性研究中的杀菌活性。随后,我们前瞻性地研究了 20 例结核病患者,在治疗结束时对他们进行了连续的ΦGFP10、Xpert MTB/RIF 和培养检测。进行了 WGS 检测,并对选定的分离株中的单核苷酸多态性(SNP)进行了检查,以检测混合感染。耐药分离株在 1:100000 时被检测到,而细胞计数门控事件的变化可以预测 ΦGFP10 检测中的杀菌活性。通过ΦGFP10 在 3 周时检测到了一名患者的新出现的耐药性,但常规检测(培养和 GeneXpert)未检测到。WGS 揭示了一个在地理上具有明显差异的广泛耐药结核病(XDR-TB)基因组,与该患者配偶的 XDR-TB 分离株相同。早期就存在变异谱系特异性 SNP,提示混合感染是新出现耐药性的病因,时间趋势为治疗期间选择提供了证据。ΦGFP10 可以检测低频耐药性,并通过 WGS 对新出现的耐药性进行特征描述。在结核病传播和耐药率高的地区,应考虑快速筛选异质性耐药。